CRP and renal cell adenocarcinoma: However, in the pivotal phase 3 JAVELIN-101 (A Study of Avelumab With Axitinib Versus Sunitinib in Advanced Renal Cell Cancer) trial, patients with mRCC treated with avelumab plus axitinib who had an elevated baseline CRP level of 10 mg/L or higher that decreased at least once below 10 mg/L (termed normalized) within 6 weeks had superior outcomes than the nonnormalized group.11 Because Tomita et al11 used the same CRP threshold that is used for mGPS assessment (low-risk mGPS vs intermediate- or high-risk mGPS), our results may also apply to ICI and TKI combination therapy.